| 尹璐瑶,梁旭东,武海荣,蔡贞玉,梁雪静,黄 晶.妊娠期缺铁性贫血的影响因素及琥珀酸亚铁片的治疗效果研究[J].现代生物医学进展英文版,2021,(9):1772-1776. |
| 妊娠期缺铁性贫血的影响因素及琥珀酸亚铁片的治疗效果研究 |
| Study on the Influencing Factors of Iron Deficiency Anemia in Pregnancy and the Therapeutic Effect of Ferrous Succinate Tablets |
| Received:November 05, 2020 Revised:November 28, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.09.038 |
| 中文关键词: 妊娠期缺铁性贫血 影响因素 琥珀酸亚铁片 疗效 |
| 英文关键词: Iron deficiency anemia in pregnancy Influencing factors Ferrous succinate tablets Curative effect |
| 基金项目:北京市科技计划项目（Z171100001017228） |
|
| Hits: 789 |
| Download times: 541 |
| 中文摘要: |
| 摘要 目的：研究妊娠期缺铁性贫血（IDA）的影响因素及琥珀酸亚铁片的治疗效果。方法：选取2017年5月~2019年6月期间我院收治的妊娠期IDA患者156例作为贫血组，选取同期于我院体检的健康妊娠期志愿者100例作为非贫血组。采用抽签法将贫血组患者分为对照组（常规治疗）和研究组（常规治疗基础上给予琥珀酸亚铁片治疗），各78例，均治疗8周。对比贫血组各亚组患者的疗效、血象指标、铁代谢指标及不良反应发生情况。采用Logistic回归分析妊娠期IDA的影响因素。结果：治疗8周后，研究组的临床总有效率高于对照组（P<0.05）。治疗8周后，研究组的平均血红蛋白量（MCH）、血红蛋白（Hb）、平均红细胞体积（MCV）高于对照组，红细胞体积分布宽度（RDW）低于对照组（P<0.05）。治疗8周后，研究组的血清铁蛋白（SF）、血清铁（SI）高于对照组，血清转铁蛋白受体（sTFR）、总铁结合力（TIBC）低于对照组（P<0.05）。两组的不良反应发生率对比无统计学差异（P>0.05）。单因素分析发现，妊娠期IDA发病与年龄、文化程度、家庭月收入、是否存在不良饮食习惯、是否有慢性胃肠道疾病史、月经初潮年龄、初次性交年龄、初次妊娠年龄、人工流产次数、产次有关（P<0.05），而与体质量指数无关（P>0.05）。Logistic 回归分析结果显示，年龄>30岁、文化程度为初中及以下、存在不良饮食习惯、伴有慢性胃肠道疾病史、月经初潮年龄<13岁、初次妊娠年龄<18岁、人工流产次数>3次是妊娠期 IDA发病的独立危险因素（P<0.05）。结论：引起妊娠期IDA发病的影响因素较多，应针对这些因素进行干预，以降低妊娠期 IDA 的发生率。琥珀酸亚铁片治疗妊娠期IDA，可有效调节铁代谢，改善红细胞形态，缓解贫血症状，且不增加不良反应发生率。 |
| 英文摘要: |
| ABSTRACT Objective: To study the influencing factors of iron deficiency anemia (IDA) in pregnancy and the therapeutic effect of Ferrous Succinate Tablets. Methods: 156 patients with IDA during pregnancy in our hospital from May 2017 to June 2019 were selected as anemia group, and 100 healthy pregnant volunteers in our hospital during the same period were selected as non anemia group. The anemia group was divided into control group (conventional treatment) and study group (Ferrous succinate tablets were given on the basis of conventional treatment) by drawing lots, 78 cases in each group, all patients were treated for 8 weeks. The curative effect, hemogram index, iron metabolism index and adverse reactions of patients in each subgroup of anemia group were compared. Logistic regression was used to analyze the influencing factors of IDA during pregnancy. Results: 8 weeks after treatment, the total effective rate of the study group was higher than that of the control group (P<0.05). 8 weeks after treatment, the meancorpuscular hemoglobin (MCH), hemoglobin (Hb), mean corpuscular volume (MCV) of the study group were higher than those of the control group, and the red blood cell volume distribution width (RDW) was higher than that of the control group(P<0.05). 8 weeks after treatment, serum ferritin (SF) and serum iron (SI) of the study group were higher than those of the control group, and the serum transferrin receptor (sTFR) and total iron binding capacity (TIBC) were lower than those of the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Univariate analysis showed that the incidence of IDA during pregnancy were related to age, education level, monthly family income, whether there were bad eating habits, whether there was a history of chronic gastrointestinal diseases, menarche age, age of first sexual intercourse, age of first pregnancy, number of induced abortion and parity(P<0.05), but not to body mass index (P>0.05). Logistic regression analysis showed that age >30 years, education level of junior high school or below, had bad eating habits, history of chronic gastrointestinal diseases, menarche age <13 years, age of first pregnancy<18 years, number of induced abortion >3 times were in dependent risk factors of IDA during pregnancy(P<0.05). Conclusion: There are many factors influencing the incidence of IDA during pregnancy, and intervention should be carried out to reduce the incidence of IDA during pregnancy. Ferrous Succinate Tablets in the treatment of IDA in pregnancy, it can effectively regulate iron metabolism, improves red blood cell morphology, relieves anemia symptoms, and does not increase the incidence of adverse reactions. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
